---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-202314"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:38:52.276631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Prelude posts Q2 net loss $30.4M; cash $255M funds operations into 2026

## Summary
- Net loss of $30.4M ($0.54/share) vs $27.4M ($0.58/share) in Q2 2022.
- R&D expense rose to $25.0M from $21.3M YoY; G&A fell to $7.4M from $8.2M.
- Cash, equivalents and marketable securities $255.0M; completed public offering raising $113M gross.
- Pipeline milestones: CDK9 (PRT2527) confirmation dose target Q1 2024; SMARCA2 degrader IND early 2024.
- Management expects cash runway into 2026; four lead programs on track for data.

## SEC filing metadata
- accession: 0001193125-23-202314
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312523202314/0001193125-23-202314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312523202314/d870924d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-202314
- JSON: https://secwatch.observer/filing/0001193125-23-202314.json
- Plain text: https://secwatch.observer/filing/0001193125-23-202314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.